Core Insights - Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing treatments for rare diseases with unmet medical needs, reporting recent accomplishments and financial results for Q2 2025 [1][10] Recent Accomplishments - The company is confident in its late-stage rare disease pipeline, with key milestones expected, including top-line results from a Phase 2a clinical trial for mild-to-moderate psoriasis with SGX302 by year-end [2] - Successful completion of a Phase 2a proof of concept study for SGX945 in Behçet's Disease, demonstrating biological efficacy [2][9] - Ongoing clinical updates for the extended HyBryte™ treatment for early-stage cutaneous T-cell lymphoma (CTCL) and plans for a Phase 3 study [2] Financial Results - No revenue was reported for Q2 2025, consistent with minimal revenue in Q2 2024 [4] - Net loss for Q2 2025 was $2.7 million, or ($0.82) per share, compared to a net loss of $1.6 million, or ($1.31) per share in Q2 2024, primarily due to increased operating expenses [5] - Research and development expenses rose to $1.7 million in Q2 2025 from $0.5 million in Q2 2024, driven by costs related to clinical trials [6] - General and administrative expenses decreased to $1.1 million in Q2 2025 from $1.2 million in Q2 2024 [7] - Cash position as of June 30, 2025, was approximately $5.1 million, excluding $1.4 million received via the ATM facility on July 1, 2025 [7] Strategic Focus - The company is evaluating strategic options, including partnerships, mergers, acquisitions, government grants, and financing opportunities to advance its late-stage pipeline [2]